<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver transplantation in adults: Patient selection and pretransplantation evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver transplantation in adults: Patient selection and pretransplantation evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liver transplantation in adults: Patient selection and pretransplantation evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lorna M Dove, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Brown, Jr, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Liver transplantation is an important treatment option for patients with acute liver failure, end-stage liver disease, and primary hepatic malignancy, though it is not the initial or primary treatment modality for most liver diseases. </p><p>Transplantation infrequently cures the underlying disease; recurrent liver disease after transplantation occurs in 0 to 100 percent of patients, depending on the disease for which transplantation was performed. Thus, the decision to list a patient for transplantation is a risk-benefit analysis in which the inherent risks of surgery, recurrent disease, and long-term immunosuppression must be weighed against the potential benefits of transplantation. These benefits differ for each patient but include improvements in survival, prevention of long-term complications, and better health-related quality of life. In most cases, the risks associated with recurrent disease do not outweigh the benefits of liver transplantation.</p><p>This topic will review the selection of patients for liver transplantation and the pretransplantation evaluation. Other issues related to liver transplantation including donor selection, living donor liver transplantation, immunosuppression following liver transplantation, and the medical management of patients who have undergone liver transplantation are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4592.html" rel="external">"Liver transplantation in adults: Deceased donor evaluation and selection"</a> and  <a class="medical medical_review" href="/z/d/html/4590.html" rel="external">"Living donor liver transplantation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression"</a> and  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients"</a>.)</p><p>The American Association for the Study of Liver Diseases and the American Society of Transplantation have developed guidelines regarding the indications for liver transplantation and the evaluation of patients being considered for liver transplantation [<a href="#rid1">1</a>]. The discussion that follows is generally consistent with those guidelines.</p><p class="headingAnchor" id="H321860393"><span class="h1">FREQUENCY OF LIVER TRANSPLANTATION BY UNDERLYING LIVER DISEASE</span><span class="headingEndMark"> — </span>According to the United Network for Organ Sharing/Organ Procurement and Transplantation Network registry, hepatocellular carcinoma and hepatitis C virus cirrhosis have been the most common diseases leading to liver transplantation, although increasing numbers of patients with alcoholic cirrhosis and nonalcoholic steatohepatitis are receiving transplants [<a href="#rid2">2,3</a>]. For additional information, see <a class="external" href="/external-redirect?target_url=http%3A%2F%2Foptn.transplant.hrsa.gov%2Fdata%2Fview-data-reports&amp;token=kQy0OGGNdHdZjdbvjX6TpVtX5cjDLPOWZpZqeYq5C2lXl412hkFpD8MgbEHsuMPlUk8iEh1hfVcR7WbPOX3cDw%3D%3D&amp;TOPIC_ID=4585" target="_blank">optn.transplant.hrsa.gov/data/view-data-reports</a>.</p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Acute liver failure</span><span class="headingEndMark"> — </span>Patients with acute liver failure are given the highest priority for liver transplantation (United Network for Organ Sharing [UNOS] status 1). In the absence of liver transplantation, patients with acute liver failure will either have a complete recovery of liver function or will die [<a href="#rid4">4</a>]. However, because it can be difficult to predict whether a given patient will recover, patients with acute liver failure should be referred to a liver transplantation center as soon as possible. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis", section on 'Liver transplantation'</a>.)</p><p>Acute liver failure is defined by the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio [INR] of ≥1.5) in a patient without cirrhosis or preexisting liver disease. While the time course that differentiates acute liver failure from chronic liver failure varies between reports, a commonly used cutoff is an illness duration of &lt;26 weeks. While there are numerous causes of acute liver failure  (<a class="graphic graphic_table graphicRef67925" href="/z/d/graphic/67925.html" rel="external">table 1</a>), viral and drug-induced hepatitis are the most common causes of acute liver failure in adults. (See  <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Cirrhosis</span><span class="headingEndMark"> — </span>The presence of cirrhosis alone is not sufficient to warrant transplantation. Transplantation is generally considered when a patient has suffered either a complication of portal hypertension or a manifestation of compromised hepatic function [<a href="#rid1">1</a>]. Variceal hemorrhage, ascites, and encephalopathy are the primary manifestations of end-stage liver disease and are designated as markers of decompensation. The onset of decompensation is associated with significantly impaired survival. Another complication of cirrhosis is the development of hepatorenal syndrome, which is an ominous marker and signals the need for immediate transplantation evaluation. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p>Patients with cirrhosis are typically candidates for liver transplantation once their biologic Model for End-stage Liver Disease (MELD) score is ≥15 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fresources%2Fallocation-calculators%2Fmeld-calculator%2F&amp;token=iRMJIIdlcCMEXBWgyUXhEj85JXUmTLBxW0uB0IuIJz7WR7PrHBxXi2mI3BwjTJvu4iYyowpPMNpkTBUTjvT81BphmAxTsPpJApITG494Mzc%3D&amp;TOPIC_ID=4585" target="_blank">MELD-Na score</a>). However, some patients with Child B cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">table 2</a>) with portal hypertension but a low MELD score may be candidates for liver transplantation. The transplantation evaluation is typically started once a patient has a MELD score &gt;10. This permits the patient to meet the transplantation team prior to the development of end-stage liver disease and ensures adequate time for the patient to complete the pretransplantation evaluation. If patients are referred for evaluation once end-stage liver disease has developed, there may not be adequate time for education, and the patient may have impaired mental status from underlying encephalopathy. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Prioritization for liver transplantation based on MELD score'</a>.) </p><p>Patients may also qualify for liver transplantation if they have a complication or condition that qualifies for standard MELD exception points. Exception points are awarded because there are some conditions associated with chronic liver disease that may result in impaired survival but are not directly accounted for in the MELD scoring system. Conditions that qualify for MELD exception points include (see  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Standard MELD exceptions in liver transplantation'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular carcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatopulmonary syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Portopulmonary hypertension (provided the mean arterial pressure can be maintained at &lt;35 mmHg with treatment)</p><p class="bulletIndent1"><span class="glyph">●</span>Familial amyloid polyneuropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Primary hyperoxaluria</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Hilar cholangiocarcinoma (provided the liver transplantation center has a UNOS-approved protocol detailing the work-up and management of patients with cholangiocarcinoma undergoing transplantation)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic artery thrombosis (occurring within 14 days of liver transplantation but not meeting criteria for status 1A)</p><p></p><p>Finally, patients may have complicating medical conditions that are related to their liver disease but that do not qualify for standard MELD exception points. Such patients can be considered for liver transplantation if their clinicians believe that the biologic MELD score does not adequately reflect a patient's true liver-related morbidity and mortality or if the complications are severely impairing the patient's quality of life. Some of these complications include (see  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Petitioning for additional MELD points'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent cholangitis in patients with primary sclerosing cholangitis who are on antibiotic suppressive therapy or require repeated biliary interventions</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory ascites</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory hepatic encephalopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory variceal hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Portal hypertensive gastropathy leading to chronic blood loss</p><p class="bulletIndent1"><span class="glyph">●</span>Intractable pruritus in a patient with primary biliary cirrhosis</p><p></p><p class="headingAnchor" id="H9953132"><span class="h2">Liver neoplasms</span><span class="headingEndMark"> — </span>Patients with some primary liver neoplasms may be candidates for liver transplantation, provided the neoplasms meet specific criteria (eg, for patients with hepatocellular carcinoma [HCC], a single lesion ≤5 cm or up to three separate lesions all &lt;3 cm, no evidence of gross vascular invasion, and no regional nodal or distant metastases). In addition, there may be a role for liver transplantation in patients with neuroendocrine tumors that have metastasized to the liver, but experience in this setting is limited [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Liver transplantation'</a>.)</p><p>Some of the liver neoplasms that have been treated with liver transplantation include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>HCC (including fibrolamellar HCC) (see  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/16571.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of fibrolamellar carcinoma", section on 'Liver transplantation'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Epithelioid hemangioendothelioma [<a href="#rid6">6-8</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Large hepatocellular adenomas (see  <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">"Hepatocellular adenoma"</a>)</p><p></p><p class="headingAnchor" id="H9953457"><span class="h2">Metabolic disorders</span><span class="headingEndMark"> — </span>Several liver-based metabolic conditions with systemic manifestations may be treated with liver transplantation. In some cases (eg, alpha-1 antitrypsin deficiency and Wilson disease), patients are cured of the underlying disease with liver transplantation, though some clinical manifestations may not be reversible.</p><p>Liver-based metabolic conditions that have been treated with liver transplantation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Familial amyloid polyneuropathy (qualifies for standard MELD exception points) [<a href="#rid9">9-11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hyperoxaluria (qualifies for standard MELD exception points) (see  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria", section on 'Transplantation'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis (qualifies for standard MELD exception points) (see  <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">"Cystic fibrosis: Hepatobiliary disease", section on 'Management'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-1 antitrypsin deficiency [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some forms of glycogen storage disease (type I and type IV) (see  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)", section on 'Liver transplantation'</a> and  <a class="medical medical_review" href="/z/d/html/2937.html" rel="external">"Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)", section on 'Treatment'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tyrosinemia (see  <a class="medical medical_review" href="/z/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Liver transplantation'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemochromatosis [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wilson disease (see  <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">"Wilson disease: Management"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute intermittent porphyria (see  <a class="medical medical_review" href="/z/d/html/7142.html" rel="external">"Acute intermittent porphyria: Management", section on 'Liver transplantation'</a>).</p><p></p><p>In the case of alpha-1 antitrypsin deficiency, cystic fibrosis, tyrosinemia, hemochromatosis, and Wilson disease, liver transplantation is usually reserved for patients who have developed end-stage liver disease or HCC.</p><p class="headingAnchor" id="H5"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Although organ allocation is centralized, criteria and contraindications to listing for liver transplantation are often transplantation center-specific. General contraindications adopted by most centers include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary disease that cannot be corrected and is a prohibitive risk for surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired immunodeficiency syndrome (AIDS)</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy outside of the liver not meeting oncologic criteria for cure</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular carcinoma with metastatic spread</p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiosarcoma</p><p class="bulletIndent1"><span class="glyph">●</span>Anatomic abnormalities that preclude liver transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled sepsis</p><p class="bulletIndent1"><span class="glyph">●</span>Acute liver failure with a sustained intracranial pressure &gt;50 mmHg or a cerebral perfusion pressure &lt;40 mmHg</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent nonadherence with medical care</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of adequate social support</p><p></p><p>For patients with alcohol-associated liver disease, some programs require a minimum period of abstinence, participation in a structured rehabilitation and abstinence program, and adequate social support to help maintain sobriety. The six-month period of abstinence is not required by many centers in patients with severe alcohol-associated hepatitis who meet center protocol. Ongoing research is needed to identify transplant candidates who are at low risk of post-transplant relapse. Pretransplant management and post-transplant outcomes for patients with alcohol-associated liver disease are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a> and  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis", section on 'Liver transplantation'</a>.)</p><p>Advanced age and human immunodeficiency virus (HIV) (but not AIDS) are examples of relative contraindications that are site-specific and are often decided on a case-by-case basis. Liver transplantation can be performed in those older than 65 years of age, provided that there has been a comprehensive evaluation for comorbidities [<a href="#rid16">16</a>].</p><p>Many transplantation centers in the United States and Europe perform liver transplantation for patients with HIV [<a href="#rid17">17-24</a>]. The available data have suggested favorable outcomes for patients who were not coinfected with hepatitis C virus (HCV) [<a href="#rid25">25-28</a>]. Initial studies on the efficacy of direct-acting antiviral therapy in coinfected patients are promising; therefore, we anticipate that further study will demonstrate similar post-transplant survival rates for HIV/HCV-coinfected patients compared with HCV-monoinfected patients [<a href="#rid29">29,30</a>]. We list patients with HIV for transplantation if they meet other criteria. We do not exclude patients with HCV coinfection because antiviral therapy for HCV improves outcomes following transplantation (see  <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients"</a>). In addition to the standard pretransplantation counseling, patients with HIV have the option of receiving an organ from an HIV-infected donor, according to the HIV Organ Policy Equity Act [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">"Kidney transplantation in adults: Kidney transplantation in patients with HIV", section on 'Donors with HIV'</a>.)</p><p>Society guidelines suggest that class 3 obesity (body mass index [BMI] ≥40) is a relative contraindication to liver transplant [<a href="#rid1">1</a>]. However, studies are not conclusive as to whether patients with increased BMI and/or metabolic syndrome have worse outcomes following transplantation [<a href="#rid32">32,33</a>]. Whether all patients with high BMI should be excluded from transplantation and what cutoff should be used (BMI &gt;40, &gt;50) remains controversial, and some centers will perform a gastric sleeve before or at the time of transplantation [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H9"><span class="h1">PRETRANSPLANTATION EVALUATION</span><span class="headingEndMark"> — </span>The goal of the pretransplantation evaluation is to assess the patient's ability to tolerate the stress of surgery, immunosuppression, and the demands of post-transplantation care. Thus, each patient undergoes an extensive cardiopulmonary evaluation, screening for occult infection or cancer, and psychosocial evaluation  (<a class="graphic graphic_table graphicRef60683" href="/z/d/graphic/60683.html" rel="external">table 3</a>). Specific testing varies depending on the patient's age, medical history, and transplantation center practice. In addition, while a certain battery of tests may initiate the work-up, more testing may be indicated if the initial test results are abnormal or if the patient has signs or symptoms of a significant comorbid illness that is not evaluated as part of the initial evaluation.</p><p class="headingAnchor" id="H26041317"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory tests that should be obtained in patients being evaluated for liver transplantation include:</p><p class="bulletIndent1"><span class="glyph">●</span>ABO-Rh blood typing</p><p class="bulletIndent1"><span class="glyph">●</span>Liver biochemical and function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, international normalized ratio [INR])</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine clearance</p><p class="bulletIndent1"><span class="glyph">●</span>Serum sodium</p><p class="bulletIndent1"><span class="glyph">●</span>Serum alpha-fetoprotein</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium and vitamin D levels</p><p class="bulletIndent1"><span class="glyph">●</span>Serum phosphatidyl ethanol (PEth)</p><p class="bulletIndent1"><span class="glyph">●</span>Serologies for cytomegalovirus, Epstein-Barr virus, varicella, human immunodeficiency virus, hepatitis A, hepatitis B, hepatitis C, rapid plasma reagin (RPR)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p class="bulletIndent1"><span class="glyph">●</span>Urine drug screen</p><p></p><p class="headingAnchor" id="H26041263"><span class="h2">Cardiopulmonary evaluation</span><span class="headingEndMark"> — </span>The cardiopulmonary evaluation is designed to evaluate for coronary artery disease, valvular heart disease, cardiomyopathy, obstructive or restrictive lung disease, hepatopulmonary syndrome, and pulmonary hypertension [<a href="#rid1">1,32-37</a>].<strong> </strong>However, there is no consensus among liver transplant programs on the optimal strategy for testing. The American Heart Association (AHA) has published a statement with a suggested protocol for coronary heart disease screening in liver transplant [<a href="#rid38">38</a>].</p><p>There are some nuances in cardiac evaluation (reduced afterload, hyperdynamic circulation, etc) that need to be taken into account in patients with cirrhosis to ensure that the work-up is appropriately vigorous. Some findings discovered during initial testing may permanently preclude transplantation, whereas others may need to be treated or corrected prior to surgery. Given the complexity, most centers work in close partnership with cardiologists and anesthesiologists knowledgeable in the physiology of cirrhosis and transplant surgery.</p><p>Morbidity and mortality from liver transplantation are increased in patients with coronary artery disease [<a href="#rid39">39</a>] or those with severe hypoxemia and elevated mean pulmonary artery pressure measurements [<a href="#rid40">40,41</a>]. However, the risk of poor outcomes does not appear to be increased in patients with mild to moderate pulmonary hypertension (pulmonary artery systolic pressure between 40 and 59 mmHg) [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Cardiovascular risk'</a> and  <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">"Management of cardiac risk for noncardiac surgery"</a>.)</p><p class="headingAnchor" id="H70836543"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>We obtain an electrocardiogram to look for signs of cardiac arrhythmias, conduction defects, signs of prior cardiac ischemia, or chamber enlargement/hypertrophy. (See  <a class="medical medical_review" href="/z/d/html/2115.html" rel="external">"ECG tutorial: Basic principles of ECG analysis"</a>.)</p><p class="headingAnchor" id="H168815067"><span class="h3">Cardiac stress testing</span><span class="headingEndMark"> — </span>To screen for coronary artery disease, we obtain noninvasive cardiac testing for all patients over 40 years of age and for those younger than 40 years if there are multiple risk factors for coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a>.)</p><p>However, the ideal evaluation of coronary artery disease prior to liver transplantation continues to evolve: </p><p class="bulletIndent1"><span class="glyph">●</span>The American Heart Association and the American College of Cardiology Foundation has suggested noninvasive stress testing in liver transplantation candidates with no active cardiac conditions if there are multiple (three or more) risk factors for coronary artery disease present (eg, diabetes, prior cardiovascular disease, left ventricular hypertrophy, age greater than 60 years, smoking, hypertension, or dyslipidemia) [<a href="#rid38">38</a>]. In addition, the use of coronary computed tomography angiography (CCTA) is emerging for patients with known cardiac disease and those with abnormal screening tests. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Established risk factors for atherosclerotic CVD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Association for the Study of Liver Diseases and the American Society of Transplantation has recommended noninvasive cardiac testing (either exercise stress testing or pharmacologic stress testing) for all adults being evaluated for liver transplantation [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some cardiologists have recommended that patients with known coronary artery disease, diabetes mellitus, or more than two cardiovascular risk factors undergo coronary angiography to assess the extent and severity of coronary artery disease [<a href="#rid43">43</a>].</p><p></p><p>Another method that is being studied for pretransplant evaluation is submaximal cardiopulmonary exercise testing. One study found that the calculated anaerobic threshold (which corresponds with cardiorespiratory reserve) predicted post-transplantation mortality [<a href="#rid44">44</a>]. Survivors of liver transplantation had higher mean anaerobic thresholds than patients who did not survive (12.0 versus 8.4 mL/min/kg). This method of pretransplantation evaluation is not in widespread use. (See  <a class="medical medical_review" href="/z/d/html/3465.html" rel="external">"Cardiopulmonary exercise testing in cardiovascular disease", section on 'Ventilatory anaerobic threshold determination'</a>.)</p><p>If initial noninvasive testing is abnormal, cardiac catheterization is indicated. If clinically significant coronary artery stenoses are present, patients should be evaluated for revascularization prior to transplantation. (See  <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">"Percutaneous coronary intervention of specific coronary lesions"</a> and  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/1544.html" rel="external">"Management of significant proximal left anterior descending coronary artery disease"</a>.)</p><p class="headingAnchor" id="H70836529"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>We obtain transthoracic echocardiography and bubble study to look for evidence of valvular heart disease, hepatopulmonary syndrome, portopulmonary hypertension, or decreased cardiac function, which may be a result of cirrhotic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Cirrhotic cardiomyopathy'</a> and  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension"</a>.)</p><p>Contrast-enhanced echocardiography is also part of the evaluation of patients with suspected hepatopulmonary syndrome. (See <a class="local">'Pulse oximetry'</a> below.) </p><p>Portopulmonary hypertension refers to pulmonary arterial hypertension that is associated with portal hypertension. Symptoms and signs of pulmonary hypertension (PH) may be difficult to recognize because they are nonspecific. Initially, patients present with fatigue, exertional dyspnea and a loud pulmonic component of the second heart sound. If the echocardiography suggests PH, additional testing is required to confirm the diagnosis and to rule out other causes of PH. (See  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H26041326"><span class="h3">Pulse oximetry</span><span class="headingEndMark"> — </span>Patients should undergo pulse oximetry to screen for hepatopulmonary syndrome. Hepatopulmonary syndrome is considered present when the following triad exists:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired oxygenation</p><p class="bulletIndent1"><span class="glyph">●</span>Intrapulmonary vascular abnormalities, referred to as intrapulmonary vascular dilatations</p><p></p><p>The presence of hepatopulmonary syndrome worsens the prognosis of patients with cirrhosis. As a result, patients with hepatopulmonary syndrome receive standard Model for End-stage Liver Disease (MELD) exception points. If the oxygen saturation on pulse oximetry is low (&lt;96 percent [<a href="#rid45">45</a>]), patients should have a blood gas obtained while breathing room air and undergo transthoracic contrast-enhanced echocardiography. Testing should also be obtained to rule out alternative causes for a low oxygen saturation. Testing to rule out other causes includes a chest radiograph, pulmonary function tests, and chest computed tomography (CT). (See  <a class="medical medical_review" href="/z/d/html/8248.html" rel="external">"Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Standard MELD exceptions in liver transplantation'</a>.)</p><p>We also perform an arterial blood gas in patients with normal pulse oximetry to calculate their age-adjusted alveolar-arterial gradient (<a class="calc calc_professional" href="/z/d/html/13447.html" rel="external">calculator 1</a>). </p><p class="headingAnchor" id="H231044574"><span class="h3">Additional testing for pulmonary disease</span><span class="headingEndMark"> — </span>The role of pulmonary function testing with diffusing capacity of the lungs for carbon monoxide to look for evidence of hepatopulmonary syndrome or primary lung disease is controversial, and there is wide variation in practice. Some transplantation centers perform such testing in all transplant candidates, while others restrict testing to patients with symptoms, smoking history, or prior known lung disease. Similarly, the use of chest radiography and chest CT scan to look for signs of pulmonary disease is variable. (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Pulmonary function tests'</a>.)</p><p class="headingAnchor" id="H70836380"><span class="h2">Cancer screening</span><span class="headingEndMark"> — </span>Cancer screening should include abdominal CT scanning or magnetic resonance imaging (MRI) to look for hepatocellular carcinoma (HCC) and a skin examination to look for evidence of skin cancer. Colorectal cancer screening is indicated for patients who are ≥45 years of age (or younger for selected patients such as those with family history of colon cancer in a first-degree relative or those with primary sclerosing cholangitis). The approach to colon cancer screening is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7565.html" rel="external">"Screening for colorectal cancer: Strategies in patients at average risk"</a> and  <a class="medical medical_review" href="/z/d/html/7572.html" rel="external">"Screening for colorectal cancer in patients with a family history of colorectal cancer or advanced polyp"</a>.)</p><p>Screening for cervical cancer, breast cancer, and prostate cancer should be obtained when indicated based on the patient's sex and age. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a> and  <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">"Screening for prostate cancer"</a>.) </p><p class="headingAnchor" id="H70836469"><span class="h2">Infectious disease evaluation and vaccinations</span><span class="headingEndMark"> — </span>In addition to obtaining serologies for several viral infections, the infectious disease evaluation should include skin testing or interferon-gamma release assay for tuberculosis. If positive, treatment may be initiated prior to transplantation or deferred until after transplantation, depending on the clinical assessment of the patient (eg, treatment should be initiated prior to transplantation if the patient has any signs or symptoms of tuberculosis). Similarly, any required dental extractions should be carried out prior to transplantation. Patients from endemic areas should be screened for coccidiomycosis or strongyloides  (<a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.) </p><p>Several vaccinations are recommended prior to liver transplantation including COVID-19 [<a href="#rid46">46</a>], hepatitis A, hepatitis B, pneumococcus, influenza, diphtheria, pertussis, and tetanus. Immunizations in solid organ transplantation candidates are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H26041297"><span class="h2">Hepatic imaging and HCC staging</span><span class="headingEndMark"> — </span>Hepatic imaging should be obtained to assess the vasculature (to ensure there are no anatomic barriers to transplantation) and, in the case of HCC, for tumor staging. This is typically done with multiphase contrast-enhanced CT scanning or contrast-enhanced MRI. If cross-sectional imaging cannot be obtained, the hepatic vasculature can be assessed with transabdominal ultrasonography with Doppler imaging or contrast-enhanced ultrasonography (where available). (See  <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Staging and prognostic scoring systems'</a> and  <a class="medical medical_review" href="/z/d/html/96352.html" rel="external">"Contrast-enhanced ultrasound for the evaluation of liver lesions", section on 'Liver transplantation'</a>.)</p><p class="headingAnchor" id="H72519455"><span class="h2">Upper endoscopy</span><span class="headingEndMark"> — </span>Upper endoscopy should be performed in patients with cirrhosis or portal hypertension to evaluate for varices. (See  <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Screening for esophageal varices'</a>.)</p><p class="headingAnchor" id="H231044639"><span class="h2">Bone density testing</span><span class="headingEndMark"> — </span>Patients should be screened for osteoporosis with bone density testing. If osteoporosis is present, treatment should be initiated prior to transplantation. Oral bisphosphonates should be used with caution in patients with esophageal varices, and patients should be aware of the importance of taking the drugs as instructed (eg, sitting upright for at least 30 minutes after taking the drug). Patients who are osteopenic should receive calcium and vitamin D supplementation. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Choice of initial therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Calcium/vitamin D'</a>.)</p><p class="headingAnchor" id="H26041270"><span class="h2">Psychosocial evaluation and education</span><span class="headingEndMark"> — </span>In addition to a standard medical evaluation, initial assessment should include an educational session discussing the risks and benefits of transplantation, including the potential for poor outcomes. A psychological evaluation and assessment of the patient's social supports is another key part of the evaluation. </p><p>The purpose of this assessment is to identify issues that may impair a successful outcome after transplantation. These potential problems include a lack of insight into the nature of the transplantation procedure, post-transplantation care, and substance use disorders. The assessment includes education of the family and/or the patient's support network. The ability to comply with complex medical and behavioral regimens is crucial after any organ transplantation procedure. Recipients must be able to incorporate complicated medication regimens, follow-up appointments, and frequent laboratory visits into their lives. Making spouses, friends, and family aware of these requirements encourages patient compliance and may improve long-term success. (See  <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a>.)</p><p>In patients with a history of a substance use disorder (drugs or alcohol), treatment should be provided prior to transplantation in an effort to increase the likelihood of success after transplantation. The treatment requirements vary among different transplantation centers but often include participation in a structured rehabilitation and abstinence program, adequate social support to help maintain sobriety, and a minimum period of sobriety prior to listing for transplantation. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">CANDIDATES FOR LIVING DONOR LIVER TRANSPLANTATION</span><span class="headingEndMark"> — </span>Living donor liver transplantation (LDLT) in adults was initiated in response to the growing shortage of organs from deceased donors [<a href="#rid47">47</a>]. Recipients considered for LDLT should fulfill the same minimal listing criteria established for deceased donor liver transplantation. The goal is to avoid premature transplantation. The optimal Model for End-stage Liver Disease (MELD) score at which patients should undergo LDLT has yet to be determined [<a href="#rid48">48</a>]. The optimal MELD score is one that identifies the recipient when the chance of liver disease-related mortality is greater than the chance of mortality from surgical complications. </p><p>Evaluation of the adult living liver donor candidate, surgical technique, and outcomes of LDLT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4590.html" rel="external">"Living donor liver transplantation in adults"</a>.)</p><p class="headingAnchor" id="H3563200513"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113977.html" rel="external">"Society guideline links: Liver transplantation"</a>.)</p><p class="headingAnchor" id="H462197354"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86455.html" rel="external">"Patient education: Liver transplant (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for liver transplantation </strong>– Indications for liver transplantation include acute liver failure, cirrhosis with complications, some liver neoplasms, and liver-based metabolic conditions with systemic manifestations. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with acute liver failure are given the highest priority for liver transplantation and should be referred to a liver transplantation center for evaluation as soon as possible. (See <a class="local">'Acute liver failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with cirrhosis are typically candidates for liver transplantation once their biologic Model for End-stage Liver Disease (MELD) score is ≥15 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fresources%2Fallocation-calculators%2Fmeld-calculator%2F&amp;token=iRMJIIdlcCMEXBWgyUXhEj85JXUmTLBxW0uB0IuIJz7WR7PrHBxXi2mI3BwjTJvu4iYyowpPMNpkTBUTjvT81BphmAxTsPpJApITG494Mzc%3D&amp;TOPIC_ID=4585" target="_blank">MELD-Na score</a>). However, the transplantation evaluation is typically started once a patient has a MELD score &gt;10. This permits the patient to meet the transplantation team prior to developing end-stage liver disease and ensures adequate time for the patient to complete the pretransplantation evaluation. (See <a class="local">'Cirrhosis'</a> above.)</p><p></p><p class="bulletIndent2">Patients with cirrhosis may also qualify for liver transplantation if they have a complication that qualifies for standard MELD exception points including hepatocellular carcinoma (HCC), hepatopulmonary syndrome, and portopulmonary hypertension. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Standard MELD exceptions in liver transplantation'</a>.)</p><p></p><p class="bulletIndent2">Finally, patients with cirrhosis may be considered for liver transplantation if they have other complications related to cirrhosis such as refractory ascites, though they do not receive standard MELD exception points. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'Petitioning for additional MELD points'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with some primary liver neoplasms (eg, HCC) may be candidates for liver transplantation, provided the neoplasms meet specific criteria. In addition, there may be a role for liver transplantation in patients with neuroendocrine tumors that have metastasized to the liver, but experience in this setting is limited. (See <a class="local">'Liver neoplasms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver-based metabolic conditions with systemic manifestations that may be treated with liver transplantation include familial amyloid polyneuropathy, primary hyperoxaluria, and cystic fibrosis. (See <a class="local">'Metabolic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Contraindications to liver transplantation include cardiopulmonary disease that cannot be corrected and is a prohibitive risk for surgery, malignancy outside of the liver not meeting oncologic criteria for cure, metastatic HCC, persistent nonadherence with medical care, and lack of adequate social support. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplantation evaluation</strong> – The goal of the pretransplantation evaluation is to assess the patient's ability to tolerate the stress of surgery, immunosuppression, and the demands of post-transplantation care. Thus, each patient undergoes an extensive cardiopulmonary evaluation, screening for occult infection or cancer, and psychosocial evaluation  (<a class="graphic graphic_table graphicRef60683" href="/z/d/graphic/60683.html" rel="external">table 3</a>). (See <a class="local">'Pretransplantation evaluation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59:1144.</a></li><li><a class="nounderline abstract_t">Yang JD, Larson JJ, Watt KD, et al. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol 2017; 15:767.</a></li><li><a class="nounderline abstract_t">Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2021; 19:580.</a></li><li><a class="nounderline abstract_t">Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.</a></li><li><a class="nounderline abstract_t">Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer 2014; 45:353.</a></li><li><a class="nounderline abstract_t">Longeville JH, de la Hall P, Dolan P, et al. Treatment of a giant haemangioma of the liver with Kasabach-Merritt syndrome by orthotopic liver transplant a case report. HPB Surg 1997; 10:159.</a></li><li><a class="nounderline abstract_t">Tepetes K, Selby R, Webb M, et al. Orthotopic liver transplantation for benign hepatic neoplasms. Arch Surg 1995; 130:153.</a></li><li><a class="nounderline abstract_t">Russo MW, Johnson MW, Fair JH, Brown RS Jr. Orthotopic liver transplantation for giant hepatic hemangioma. Am J Gastroenterol 1997; 92:1940.</a></li><li><a class="nounderline abstract_t">Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77:64.</a></li><li><a class="nounderline abstract_t">Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 2008; 14:563.</a></li><li><a class="nounderline abstract_t">Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013; 47:157.</a></li><li><a class="nounderline abstract_t">Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008; 40:1492.</a></li><li><a class="nounderline abstract_t">Carey EJ, Iyer VN, Nelson DR, et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis. Liver Transpl 2013; 19:1370.</a></li><li><a class="nounderline abstract_t">Brandhagen DJ, Alvarez W, Therneau TM, et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000; 31:456.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Brandhagen DJ, Gish RG, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129:494.</a></li><li><a class="nounderline abstract_t">Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13:1382.</a></li><li class="breakAll">Roland MS, Carlson L. Liver and kidney transplantation in HIV-infected patients: A preliminary multi-site experience. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 655.</li><li class="breakAll">Ragni M NG, Heaton N. Antiretroviral therapy and mortality among HIV-positive liver transplant recipients. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28 2002; Seattle, Washington. Abstract 125.</li><li><a class="nounderline abstract_t">Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72:1684.</a></li><li class="breakAll">Fung J. Clinical experiences with HIV and transplantation. Oral Presentation. American Society of Transplantation (AST) Winter Symposium; January 19, 2002; Olympic Valley, California.</li><li><a class="nounderline abstract_t">Wreghitt T. Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684. Transplantation 2001; 72:1594.</a></li><li><a class="nounderline abstract_t">Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33:3646.</a></li><li><a class="nounderline abstract_t">Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76:370.</a></li><li><a class="nounderline abstract_t">Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239.</a></li><li><a class="nounderline abstract_t">Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS 2011; 25:777.</a></li><li><a class="nounderline abstract_t">Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85:359.</a></li><li><a class="nounderline abstract_t">Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716.</a></li><li><a class="nounderline abstract_t">Zarinsefat A, Gulati A, Shui A, et al. Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV. JAMA Surg 2022; 157:240.</a></li><li><a class="nounderline abstract_t">Antonini TM, Coilly A, Rossignol E, et al. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study. Transplantation 2018; 102:119.</a></li><li><a class="nounderline abstract_t">Grant JL, Hawkins C, Brooks H, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS 2016; 30:93.</a></li><li><a class="nounderline abstract_t">Malani P. HIV and Transplantation: New Reasons for HOPE. JAMA 2016; 316:136.</a></li><li><a class="nounderline abstract_t">Barone M, Viggiani MT, Losurdo G, et al. Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. Aliment Pharmacol Ther 2017; 46:236.</a></li><li><a class="nounderline abstract_t">Saab S, Lalezari D, Pruthi P, et al. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int 2015; 35:164.</a></li><li><a class="nounderline abstract_t">Zamora-Valdes D, Watt KD, Kellogg TA, et al. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology 2018; 68:485.</a></li><li><a class="nounderline abstract_t">Zoghbi GJ, Patel AD, Ershadi RE, et al. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003; 92:1066.</a></li><li><a class="nounderline abstract_t">Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401.</a></li><li><a class="nounderline abstract_t">Guckelberger O, Mutzke F, Glanemann M, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006; 12:394.</a></li><li><a class="nounderline abstract_t">Cheng XS, VanWagner LB, Costa SP, et al. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation 2022; 146:e299.</a></li><li><a class="nounderline abstract_t">Plotkin JS, Scott VL, Pinna A, et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2:426.</a></li><li><a class="nounderline abstract_t">Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174.</a></li><li><a class="nounderline abstract_t">Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002; 8:382.</a></li><li><a class="nounderline abstract_t">Harinstein ME, Iyer S, Mathier MA, et al. Role of baseline echocardiography in the preoperative management of liver transplant candidates. Am J Cardiol 2012; 110:1852.</a></li><li><a class="nounderline abstract_t">Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58:223.</a></li><li><a class="nounderline abstract_t">Prentis JM, Manas DM, Trenell MI, et al. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl 2012; 18:152.</a></li><li><a class="nounderline abstract_t">Arguedas MR, Singh H, Faulk DK, Fallon MB. Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol 2007; 5:749.</a></li><li class="breakAll">COVID-19 Vaccine FAQ Sheet https://www.myast.org/sites/default/files/2021%2003%2018%20COVID19%20VACCINE%20FAQS_update.pdf (Accessed on March 20, 2021).</li><li><a class="nounderline abstract_t">Brown RS Jr, Russo MW, Lai M, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348:818.</a></li><li><a class="nounderline abstract_t">Wong TC, Fung JY, Pang HH, et al. Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome. Hepatology 2021; 73:2441.</a></li></ol></div><div id="topicVersionRevision">Topic 4585 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716201" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28013117" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32531342" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12484709" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604263" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Liver transplantation for malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174860" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of a giant haemangioma of the liver with Kasabach-Merritt syndrome by orthotopic liver transplant a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848084" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Orthotopic liver transplantation for benign hepatic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382077" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Orthotopic liver transplantation for giant hepatic hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724437" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383093" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169427" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Liver transplantation and transthyretin amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589136" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alpha-1-antitrypsin deficiency: outcomes after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019185" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655270" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083706" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17902123" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17902123" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17902123" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726833" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Liver transplantation in adults coinfected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726833" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Liver transplantation in adults coinfected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726816" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750549" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Solid organ transplantation in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883195" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12619020" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412058" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18301332" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22328294" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34985513" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846559" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26731756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404170" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HIV and Transplantation: New Reasons for HOPE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28488418" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313970" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The impact of obesity on patient survival in liver transplant recipients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29457842" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583357" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12540791" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498651" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Validation of cardiovascular risk scores in a liver transplant population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36252095" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9346688" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762853" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965583" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcome of liver transplantation for patients with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021513" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of baseline echocardiography in the preoperative management of liver transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737011" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiovascular risk assessment of the liver transplant candidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21898768" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392034" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Utility of pulse oximetry screening for hepatopulmonary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392034" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Utility of pulse oximetry screening for hepatopulmonary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606737" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A survey of liver transplantation from living adult donors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33006772" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
